High-performance liquid chromatographic analysis of nitrendipine in human plasma using ultraviolet detection and single-step solid-phase sample preparation

Stability of 5 mg/mL Nitrendipine Oral Suspension in Syrspend® SF PH4

Background

Nitrendipine is prescribed to children for the treatment of primary hypertension (off-label use). Available specialties (Nidrel®, Baypress® and others generic drugs) are only marketed in tablet form, which is unsuitable for pediatric use. A hospital preparation of nitrendipine oral suspension at 5 mg/mL was developed. The aim of the study was to determine physicochemical and microbiological stability of the nitrendipine oral suspension in order to set a shelf life for the preparation.

Methods

A validated high-performance liquid chromatographic (HPLC) method was developed for the assay of nitrendipine. Nitrendipine oral suspensions were prepared using 20 mg Nidrel® tablets and suspending vehicle Syrspend® SF PH4. These preparations were packaged in amber glass bottles and stored at room temperature. The physicochemical (pH, osmolality, nitrendipine concentration, macroscopic changes) and microbiological stability of the preparation was tested over 90 days. Nitrendipine concentration at day 0 was considered as 100 % and nitrendipine concentration in subsequent samples greater than 95 % were considered stable.

Results

The developed HPLC method was validated in terms of linearity, accuracy, precision and specificity. After 90 days, no significant pH and osmolality variation was observed. No microbial growth was noted. Concentrations of nitrendipine were found to be always higher 95 % of the initial concentration.

Conclusions

Nitrendipine oral suspensions 5 mg/mL are stable for at least 90 days when stored at temperature room and in amber glass bottles. This suspension is more suitable for children than tablets and allows obtaining accurate doses based on patient’s body weight.

Solubility and Thermodynamic Analysis of Antihypertensive Agent Nitrendipine in Different Pure Solvents at the Temperature Range of 298.15 to 318.15°K

The aim of the present study was to ascertain the solubility of nitrendipine (NP), an antihypertensive drug in six different pure solvents such as water, ethyl acetate (EA), ethanol, isopropyl alcohol (IPA), polyethylene glycol-400 (PEG-400), and Transcutol at temperature from 298.15 to 318.15 K under atmospheric pressure (p) of 0.1 MPa. Experimental solubility data of NP was fitted with Apelblat and ideal models. The mole fraction solubility of NP was found maximum in PEG-400 (6.85 × 10^-2 at 318.15 K) followed by Transcutol (4.65 × 10^-2 at 318.15 K), EA (1.68 × 10^-2 at 318.15 K), ethanol (2.83 × 10^-3 at 318.15 K), IPA (2.69 × 10^-3 at 318.15 K), and water (1.29 × 10^-7 at 318.15 K). The dissolution activity of NP was observed as an endothermic, spontaneous, and an entropy-driven in most of studied pure solvents. The solubility data of NP obtained in the present study could be useful in purification, recrystallization, and dosage forms design of NP.

Development of a LC-ESI-MS3 method for determination of nitrendipine in human plasma

A novel and sensitive method utilizing high performance liquid chromatography coupled with electrospray ionization source tandem mass spectrometry (LC-ESI-MS(3)) was developed for the first time in order to analyze nitrendipine in human plasma samples. Human plasma samples were prepared by protein precipitation with acetonitrile and well resolved on a 100 mm reversed-phase column in gradient elution with 0.05% (v/v) formic acid in acetonitrile as the mobile phase. Determination was performed in MS(3) scan mode for nitrendipine and in the multiple reaction monitoring (MRM) mode for nimodipine (internal standard). This method, having a lower limit of quantification (LLOQ) of 0.05 ng/mL when using a 100 μL sample aliquot (5 pg/sample), is acceptable for calibration of the linearity and repeatability and is of better sensitivity than the reported methods (>0.25 ng/mL). The major advantages of the method are that small sample volume (100 μL) is required, simple sample processing technique, high sensitivity and excellent selectivity is guaranteed by the MS(3) detection. The proposed validated method has been successfully applied to a clinical study on nitrendipine.

Simultaneous determination of nitrendipine and one of its metabolites in plasma samples by gas chromatography with electron-capture detection

A sensitive method for GC-ECD simultaneous determination of nitrendipine and its pyridine metabolite M1 in human plasma is described. Felodipine was used as the internal standard. The plasma samples were extracted with toluene. One microlitre of the extract was injected onto the capillary column (polymethylsiloxane) and measured with electron-capture detector. The developed method showed to be linear over the range 0.25-70 for nitrendipine and 0.3-61 ng/ml for its metabolite M1 with an inter-day and intra-day precision in terms of R.S.D. lower than 8% except the concentrations near lowest limit of quantification (LLOQ) (<11% R.S.D.). The LLOQ for nitrendipine was 0.25 and 0.3 ng/ml for its metabolite, respectively. The analytical recovery was 94% for nitrendipine and 89% for its pyridine metabolite M1. This GC-ECD method was developed for being used in clinical pharmacokinetic studies.

Development and validation of a reversed-phase HPLC method for determination of nitrendipine in rat plasma: application to pharmacokinetic studies

A simple and sensitive method for the determination of nitrendipine in rat plasma was developed using high-performance liquid chromatography (HPLC). The procedure involves extraction of nitrendipine in dichloromethane/sodium hydroxide, followed by reversed phase HPLC using a Waters, Spherisorb ODS2 (250 x 4.6 mm, 5 microm) column and UV detection at 238 nm. The retention times of nitrendipine and internal standard (felodipine) were 5.0 min and 7.5 min, respectively. The calibration curves were linear over the range of 5 ng/mL (lower limit of quantification, LOQ) to 200 ng/mL for nitrendipine. The intra- and inter-day coefficients of variation for all criteria of validation were less than 15% over the linearity range. The sensitivity and precision of the method were within the accepted limits (< 15%) throughout the validation period. The present method was also successfully applied for the study of plasma pharmacokinetics of nitrendipine loaded solid lipid nanoparticles (SLN) in rats.

Validated LC–MS–MS method for determination of m-nisoldipine polymorphs in rat plasma and its application to pharmacokinetic studies

A sensitive and specific liquid chromatography-tandem mass spectrometric (LC-MS-MS) method has been developed to determine m-nisoldipine in rat plasma. Sample was pretreated by a single-step protein precipitation with acetonitrile, in contrast to the liquid-liquid procedure frequently used for the extraction of 1,4-dihydropyridines from biologic samples. Separation of analyte and internal standard (I.S.) was performed on a Symmetry RP-C(18) analytic column (50 mm x 4.6 mm, 3.5 microm) with a mobile phase consisting of acetonitrile-water (80:20, v/v) at a flow rate of 0.5 ml/min. The API 4000 triple quadrupole mass spectrometer was operated in multiple reaction monitoring (MRM) scan mode using TurboIonSpray ionization (ESI) source. The method was sensitive with a lower limit of quantification (LLOQ) of 0.2 ng/mL, with good linearity (r>or=0.9982) over the linear range of 0.2-20 ng/mL. All the validation data, such as accuracy, precision, and inter-day repeatability, were within the required limits. The method was successfully applied to pharmacokinetic and relative bioavailability studies of m-nisoldipine polymorphs in rats.

Quantitative Determination of the Calcium Channel Antagonists Amlodipine, Lercanidipine, Nitrendipine, Felodipine, and Lacidipine in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry

A sensitive and specific liquid chromatography-tandem mass spectrometric method has been developed and validated for the quantification of the five 1,4-dihydropyridine calcium channel antagonists amlodipine, lercanidipine, nitrendipine, felodipine, and lacidipine in human plasma. Sample preparation involved solid-phase extraction on RP-C18 cartridges with good recovery for all the compounds. Sample analysis was performed on a Luna RP-C18 analytical column (15 mm x 2 mm ID, 3.0 microm) with a Sciex API 365 triple quadrupole mass spectrometer with turboionspray source and multiple reaction monitoring. The method is sensitive with a limit of detection below 1 ng/mL for each drug in plasma, with good linearity (r(2) > 0.998), over the therapeutic concentration range (1 to 40 ng/mL). All the validation data, such as accuracy, precision, and interday repeatability, were within the required limits. The method can be used for pharmacokinetic studies and therapeutic drug monitoring of the compounds in humans.